<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669370</url>
  </required_header>
  <id_info>
    <org_study_id>2005-002484-87</org_study_id>
    <secondary_id>EudraCT no 2005-002484-87</secondary_id>
    <nct_id>NCT00669370</nct_id>
  </id_info>
  <brief_title>Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer</brief_title>
  <acronym>GAST-TaxXel</acronym>
  <official_title>Biweekly Docetaxel (Taxotere®)in Combination With Capecitabine (Xeloda®)as First-Line Treatment in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the quality of life in patients with gastric cancer who receive combination
      treatment with docetaxel and capecitabine. Secondary endpoints are time to progression,
      overall response rate and overall survival.

      Study treatment will continue until disease progression or unacceptable toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GAST-TaxXel is an open, phase II, single arm, non-randomized, Finnish multicenter trial. At
      least 50 subjects will be enrolled.

      Primary endpoint:

      To determine the quality of life (EORTC QLQ-C30 and QLQ-STO22) in patients with gastric
      cancer who receive combination treatment with Taxotere and Xeloda.

      Secondary endpoint:

      To evaluate time to progression (TTP), overall response rate (ORR) and overall survival (OS).

      Quality of life: to evaluate that QOL does not deteriorate from baseline. Quality of life is
      measured using EORTC QLQ-C30 and QLQ-STO22 with physical functioning score as the primary
      variable.

      Efficacy: time to progression, overall response rate, overall survival Time to progression is
      defined as time elapsed from inclusion to first documented progression or death whatever the
      reason. Overall response rate is assessed according to the RECIST criteria. Overall survival
      is defined as time elapsed from inclusion to death.

      Safety: clinical and laboratory toxicities or symptomatology will be graded according to
      NCI-CTC criteria.

      Statistical considerations:

      The primary variable, physical functioning score measured by the EORTC QLQ-C30 and QLQ-STO22
      instrument, will be analyzed using a paired t-test (change from baseline after two treatment
      cycles). A 95% confidence interval will also be calculated for the primary variable. Median
      TTP and OS will be estimated using the Kaplan-Meier method. The ORR will be summarized.
      Safety variables will be summarized descriptively.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the quality of life (EORTC QLQ-C30 and QLQ-STO22)</measure>
    <time_frame>at baseline and on day 1 at every cycle, at the end of study and every 8 week until progress</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate time to progression (TTP), overall response rate (ORR) and overall survival (OS).</measure>
    <time_frame>every 3 cycles, at the end of study and every 3 month</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stomach Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and capecitabine</intervention_name>
    <description>biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days</description>
    <other_name>Taxotere</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically confirmed advanced, inoperable gastric adenocarcinoma

          -  age ≥18 years

          -  WHO performance status ≤ 2

          -  Stage IV

          -  Measurable (according to RECIST criteria) or evaluable lesion

          -  No previous chemotherapy, except adjuvant chemotherapy ≥ 6 months ago

          -  Adequate hematological function (neutrophils ≥ 1.5 x 109/l and platelets ≥ 100 x
             109/l, Hb ≥ 100 g/l (after transfusion when needed)

          -  Adequate renal function (serum creatinine ≤ 1.25 x upper normal limit)

          -  Adequate liver function (total serum bilirubin ≤ 1.25 x upper normal limit or ALAT ≤ 3
             x upper normal limit; in case of liver metastasis: total serum bilirubin ≤ 1.5 x upper
             normal limit, ALAT ≤ 5 x upper normal limit)

          -  AFOS ≤ 2.5 x upper normal limit (unless bone metastases)

          -  Consent form signed and dated before inclusion

          -  Able to comply with the scheduled follow-up and with the management of toxicities.

        Exclusion Criteria:

          -  Pregnant or lactating women (or potentially fertile women not using adequate
             contraception)

          -  Presence of CNS metastases

          -  Unresolved bowel obstruction or subobstruction

          -  Chronic diarrhea

          -  Clinically significant malabsorption syndrome

          -  Inability to swallow tablets

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Concurrent severe and/or uncontrolled co-morbid medical condition such as uncontrolled
             infection, hypertension, ischemic heart disease, myocardial infarction within previous
             6 months, congestive heart failure

          -  History of previous or concurrent malignancy within the previous 5 years except
             curatively treated carcinoma in situ of the uterine cervix or basal cell carcinoma of
             the skin

          -  History of prior serious allergic reactions such as anaphylactic shock.

          -  Peripheral neuropathy ≥ grade 2, unless related to mechanical etiology

          -  Concurrent use of corticosteroids unless chronic treatment (i.e. initiated &gt; 6 months
             prior to study entry) at low doses (≥ 20 mg methylprednisolone or equivalent)

          -  History of allergy to drugs containing the excipient TWEEN 80® and/ or 5-
             fluorouracil.

          -  Lack of physical integrity of the upper gastrointestinal tract.

          -  Concomitant administration of any other experimental drug under investigation:
             concurrent treatment with any other anti-cancer therapy.

          -  Major surgery within 4 weeks prior to study treatment start, or lack of complete
             recovery from the effects of major surgery.

          -  Patients who cannot be regularly followed up for psychological, social, family or
             geographic reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raija Ristamäki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology and Radiotherapy, Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raija Ristamäki, MD, PhD</last_name>
    <phone>358-2-313-0520</phone>
    <email>raija.ristamaki@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seppo Pyrhönen, professor</last_name>
    <phone>358-2-313-2800</phone>
    <email>seppo.pyrhonen@tyks.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Päivi Auvinen, MD, PhD</last_name>
      <phone>358-17-172-907</phone>
      <email>paivi.auvinen@kuh.fi</email>
    </contact>
    <investigator>
      <last_name>Päivi Auvinen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heli Virsunen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu Univerity Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raija Kallio, Md, PhD</last_name>
      <phone>358-8-315-2011</phone>
      <email>raija.kallio@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Raija Kallio, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Satakunta District Hospital</name>
      <address>
        <city>Pori</city>
        <zip>22850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maija-Leena Murashev, MD</last_name>
      <phone>358-2-62771</phone>
      <email>maija.murashev@satshp.fi</email>
    </contact>
    <investigator>
      <last_name>Maija-Leena Murashev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tampere</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tapio Salminen, MD</last_name>
      <phone>358-3-311-611</phone>
      <email>tapio.salminen@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Tapio Salminen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology and Radiotherapy, turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raija ristamäki, MD, PhD</last_name>
      <phone>358-2-313-0520</phone>
      <email>raija.ristamaki@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Eija Korkeila, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raija Ristamäki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seppo Pyrhönen, professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vaasa Distric Hospital</name>
      <address>
        <city>Vaasa</city>
        <zip>65100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjatta Mikkola, MD</last_name>
      <phone>358-6-323-2918</phone>
      <email>marjatta.mikkola@vshp.fi</email>
    </contact>
    <investigator>
      <last_name>Marjatta Mikkola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <last_update_submitted>April 29, 2008</last_update_submitted>
  <last_update_submitted_qc>April 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Raija Ristamäki</name_title>
    <organization>Department of Oncology and Radiotherapy, Turku University Hospital</organization>
  </responsible_party>
  <keyword>advanced gastric cancer</keyword>
  <keyword>adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

